A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

Marisa Tungsiripat, Douglas Kitch, Marshall J. Glesby, Samir K. Gupta, John W. Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F. Rooney, Judith A. Aberg

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.

Original languageEnglish (US)
Pages (from-to)1781-1784
Number of pages4
JournalAIDS
Volume24
Issue number11
DOIs
StatePublished - Jul 17 2010

Fingerprint

Tenofovir
Dyslipidemias
Lipids
LDL Cholesterol
Placebos
Therapeutics
Cross-Over Studies
HIV

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy : ACTG 5206. / Tungsiripat, Marisa; Kitch, Douglas; Glesby, Marshall J.; Gupta, Samir K.; Mellors, John W.; Moran, Laura; Jones, Lynne; Alston-Smith, Beverly; Rooney, James F.; Aberg, Judith A.

In: AIDS, Vol. 24, No. 11, 17.07.2010, p. 1781-1784.

Research output: Contribution to journalArticle

Tungsiripat, M, Kitch, D, Glesby, MJ, Gupta, SK, Mellors, JW, Moran, L, Jones, L, Alston-Smith, B, Rooney, JF & Aberg, JA 2010, 'A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206', AIDS, vol. 24, no. 11, pp. 1781-1784. https://doi.org/10.1097/QAD.0b013e32833ad8b4
Tungsiripat, Marisa ; Kitch, Douglas ; Glesby, Marshall J. ; Gupta, Samir K. ; Mellors, John W. ; Moran, Laura ; Jones, Lynne ; Alston-Smith, Beverly ; Rooney, James F. ; Aberg, Judith A. / A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy : ACTG 5206. In: AIDS. 2010 ; Vol. 24, No. 11. pp. 1781-1784.
@article{2ab82520f840483189ff798df8ab38bd,
title = "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206",
abstract = "Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.",
author = "Marisa Tungsiripat and Douglas Kitch and Glesby, {Marshall J.} and Gupta, {Samir K.} and Mellors, {John W.} and Laura Moran and Lynne Jones and Beverly Alston-Smith and Rooney, {James F.} and Aberg, {Judith A.}",
year = "2010",
month = "7",
day = "17",
doi = "10.1097/QAD.0b013e32833ad8b4",
language = "English (US)",
volume = "24",
pages = "1781--1784",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy

T2 - ACTG 5206

AU - Tungsiripat, Marisa

AU - Kitch, Douglas

AU - Glesby, Marshall J.

AU - Gupta, Samir K.

AU - Mellors, John W.

AU - Moran, Laura

AU - Jones, Lynne

AU - Alston-Smith, Beverly

AU - Rooney, James F.

AU - Aberg, Judith A.

PY - 2010/7/17

Y1 - 2010/7/17

N2 - Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.

AB - Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.

UR - http://www.scopus.com/inward/record.url?scp=77954319572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954319572&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32833ad8b4

DO - 10.1097/QAD.0b013e32833ad8b4

M3 - Article

C2 - 20495438

AN - SCOPUS:77954319572

VL - 24

SP - 1781

EP - 1784

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -